Home | HealthCare Royalty Partners

Advancing Biopharmaceutical Innovation with Creative Capital Solutions

HealthCare Royalty is a leading royalty acquisition company focused on commercial or near-commercial stage biopharmaceutical products.

Royalty Monetization

Corporate Financing

$5B+

Invested in more than 85 biopharma products since inception

NY

New York Metro Area

CA

San Francisco

MA

Boston

UK

London

34

Team Members

Meet Our Team

Team

Interview with Dr. Robert Langer, HCRx Senior Advisor

Interview with Gary Lyons, HCRx Senior Advisor

Interview with Dr. Greg Went, Former Chairman & CEO, Adamas Pharmaceuticals (December 2017)

Interview with Julie McHugh, HCRx Senior Advisor

Interview with Julie Anne Smith, Former President and CEO, Raptor Pharmaceuticals

Interview with Nat Ricciardi, HCRx Senior Advisor

Spotlight

Latest News

REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million

Liquidia Corporation Strengthens Financial Position by Amending HealthCare Royalty Agreement to Incrementally Add Up to $100 Million

Heidelberg Pharma Amends Royalty Financing with HealthCare Royalty

GENFIT Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang Resolution Plan

Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions

Liquidia Corporation Announces Raise of $67.5 Million from New Common Stock Financings and $32.5 Million Advance from HealthCare Royalty Under Current Financing Agreement

HealthCare Royalty and Blue Owl Announce $250M Debt Financing with TG Therapeutics

Valinor Pharma Announces Acquisition by Grünenthal with a Total Deal Value of Approximately $250 Million

Grünenthal acquires US-company Valinor Pharma and becomes global owner of Movantik®

OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA’s Profit Share Payments